drugset
drugset / Trial / NCT00489203

Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

NCT00489203 ↗

Phase 2 Completed 140 enrolled Fred Hutchinson Cancer Center
RandomizedParallel-groupQuadruple-blindSupportive care

Summary

RATIONALE: Beclomethasone dipropionate may be effective in preventing acute graft-versus-host disease in patients undergoing a stem cell transplant for hematologic cancer. PURPOSE: This randomized phase II trial is studying how well beclomethasone dipropionate works in preventing acute graft-versus-host disease in patients undergoing a donor stem cell transplant for hematologic cancer.

Timeline

Start
2007-04
Primary completion
2010-11
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject beclomethasone dipropionate Other / unclassified — Oral
Background Methotrexate Small molecule — —
Background Tacrolimus Small molecule — —

Indications

Burkitt lymphoma Hodgkins lymphoma MALT lymphoma acute myeloid leukemia with 11q23 abnormalities acute myeloid leukemia with t(8;21)(q22;q22) translocation acute myeloid leukemia, inv(16)(p13.1;q22) acute myeloid leukemia, t(16;16)(p13.1;q22) adult T-cell leukemia/lymphoma adult acute lymphoblastic leukemia atypical chronic myeloid leukemia, BCR-ABL1 negative blast phase chronic myelogenous leukemia, BCR-ABL1 positive childhood acute lymphoblastic leukemia childhood acute myeloid leukemia childhood myelodysplastic syndrome chronic eosinophilic leukemia chronic lymphocytic leukemia/small lymphocytic lymphoma chronic neutrophilic leukemia essential thrombocythemia extramedullary plasmacytoma grade III lymphomatoid granulomatosis graft versus host disease hairy cell leukemia juvenile myelomonocytic leukemia large-cell immunoblastic lymphoma leukemia, myeloid, accelerated-phase mantle cell lymphoma mycosis fungoides and variants nodal marginal zone B-cell lymphoma plasma cell myeloma primary myelofibrosis primary plasmacytoma of the bone